Research Projects & Grants

• Selpercatinib LOXO-292, Role: PI, Status: Completed

College/University

• UCI - BMS CA 180-097: A phase II trial of dasatinib (Sprycel®) in subjects with hormone-refractory prostate cancer previously treated with chemotherapy, Role: Investigator, University of California, Irvine, (08/2010 - 08/2011) Status: Completed
• Millennium 03-1218/34102-033 MUSC CTO #100822: VELCADE® (bortezomib) for injection therapy for early relapsed prostate cancer, Role: Investigator, Medical University of South Carolina, (09/2009 - 09/2010) Status: Completed
• Phase II trial of serum Micro RNA-371 in detecting active germ cell tumors in patients with suspected regional disease –(MAGESTIC Trial: MiRNA in detecting Active Germ cell tumors in Early Suspected and metastaTIC disease Trial), Role: Investigator, University of Southern California, (10/2024 - 10/2025) Status: Approved

Default Sponsor Type

• Phase II trial of serum Micro RNA-371 in detecting active germ cell tumors in patients with suspected regional disease –(MAGESTIC Trial: MiRNA in detecting Active Germ cell tumors in Early Suspected and metastaTIC disease Trial), Role: Investigator, University of Southern California, (10/2024 - 10/2025) Status: Approved

Federal

• SWOG - PACCT-1: Program of the assessment of clinical tests (PACCT-1): Trial assigning individualized options for treatment: the TAILORx trial, Role: PI, Eastern Cooperative Oncology Group, (11/2024 - 11/2025) Status: Approved
• CALGB-40502: A randomized phase III trial of weekly paclitaxel compared to weekly nanoparticle albumin bound NAB-paclitaxel or ixabepilone with or without bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer, Role: Investigator, National Cancer Institute/NIH/DHHS, (07/2016 - 07/2017) Status: Completed
• NASBP B-27.1 A trial to evaluate the worth of serum ErbB-2 extracellular domain and serum ErbB-2 antibodies in predicting response to preoperative chemotherapy and long-term outcome in patients with operable breast cancer who are participating in NSABP Protocol B-27, Role: Investigator, National Cancer Institute/NIH/DHHS, (07/2009 - 07/2010) Status: Completed
• NSABP C-06. A clinical trial comparing oral Uracil/Ftorafur plus leucovorin with 5-fluorouraceil (5-FU) plus leucovorin in the treatment of patients stages II and III carcinoma of the colon, Role: Investigator, National Cancer Institute/NIH/DHHS, (08/2008 - 08/2009) Status: Completed
• Lactic Acidosis as a Potential Mechanism of Unexpected Cardiac Toxicity following Chemoradiation Therapy for Non-small Cell Lung Cancer, Role: Research Coordinator/Nurse, National Cancer Institute/NIH/DHHS, (11/2023) Status: Approved

For Profit Organization

• SWOG-S0820: A double blind placebo-controlled trial of eflornithine and sulindac to prevent recurrence of high risk adenomas and second primary colorectal cancers in patients with stage 0-III colon cancer, phase III - preventing adenomas of the colon with eflornithine and sulindac (PACES), Role: Investigator, Southwest Oncology Group, (09/2024 - 09/2025) Status: Approved
• SWOG-A011106:ALTernate approaches for clinical stage II or III estrogen receptor positive breast cancer NeoAdjuvant TreEatment (ALTERNATE) in postmenopausal women: a phase III study, Role: Investigator, Southwest Oncology Group, (09/2024 - 09/2025) Status: Approved
• SWOG-A081105: randomized study of Erlotinib VS Observation in patients with completely resected Epidermal Growth Factor Receptor (EGFR) mutant Non-small Cell Lung Cancer (NSCLC), Role: PI, Southwest Oncology Group, (09/2024 - 09/2025) Status: Approved
• SWOG A011202: a randomized phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (cT1-3 N1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy, Role: Investigator, Southwest Oncology Group, (08/2024 - 08/2025) Status: Approved
• Amgen Inc., 20190135: A Phase 1b Study Evaluating the Safety, Tolerability, and Efficacy of AMG 510 (plNN Sotorasib) in Combination with Panitumumab and in Combination with Panitumumab and Chemotherapy in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation (CodeBreak 101 Subprotocol H), Role: PI, Amgen, Inc., (06/2024 - 06/2025) Status: Approved
• J2J-MC-JZLH EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence, Role: Investigator, Eli Lilly & Co., (06/2024 - 06/2025) Status: Approved
• Southwest Oncology Group (SWOG) Protocol N063D/BIG2-06-ALTTO - Adjuvant lapatinib and/or trastuzumab treatment optimisation study. A randomized, multi-center, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer, Role: Investigator, Southwest Oncology Group, (03/2025 - 03/2026) Status: Approved
• SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer, Role: Investigator, Southwest Oncology Group, (04/2024 - 09/2024) Status: Completed
• Amgen 20190135: A Phase 1b/2, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (plNN Sotorasib) in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation, Role: PI, Amgen, Inc., (02/2025 - 02/2026) Status: Approved
• SWOG E1697: Phase III randomized study of four weeks high dose IFN-a2b in stage T2bN0, T3a-bN0, and T1-4, N1a2a (microscopic) melanoma, Role: Investigator, Southwest Oncology Group, (02/2025 - 02/2026) Status: Approved
• Amgen 20190135: A Phase 1b, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation Amgen 20190135-C: A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Combination With RMC-4630 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101 Subprotocol C), Role: PI, Amgen, Inc., (12/2024 - 12/2025) Status: Approved
• SWOG-S1207: Phase III randomized, placebo-controlled clinical trial evaluating the use of adjuvant endocrine therapy +/- one year of EVEROLIMUS in patients with high-risk hormone receptor-positive AND HER2/neu negative breast cancer e3 breast cancer study - evaluating everolimus with endocrine therapy, Role: Investigator, Southwest Oncology Group, (12/2024 - 12/2025) Status: Approved
• ATARA Biotherapeutics, Inc. ATA129-EBV-302: Multicenter, Open Label, Phase 3 study of Tabelecleucel for solid organ or allogeneic hematopoietic cell transplant subjects with Epstein-Barr virus-associated post-transplant lymphoproliferative disease after failure of Rituximab or Rituximab and Chemotherapy (ALLELE study), Role: Investigator, Atara Biotherapeutics, Inc., (12/2024 - 12/2025) Status: Approved
• Southwest Oncology Group (SWOG) S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in rare tumors, Role: Investigator, Southwest Oncology Group, (12/2024 - 12/2025) Status: Approved
• A Phase 3 Open-label, Randomized Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03), Role: Investigator, AstraZeneca Pharmaceuticals, L.P. (USA), (01/2024 - 01/2026) Status: Approved
• SWOG EA5142:adjuvant nivolumab in resected lung cancers (ANVIL) a randomized phase III study of nivolumab after surgical resection and adjuvant chemotherapy in non-small cell lung cancers, Role: PI, Southwest Oncology Group, (11/2024 - 11/2025) Status: Approved
• SWOG-S1216: a phase III randomized trial comparing androgen deprivation therapy + TAK-700 with androgen deprivation therapy + bicalutamide in patients with newly diagnosed metastatic hormone sensitive prostate cancer, Role: Investigator, Southwest Oncology Group, (10/2024 - 10/2025) Status: Approved
• SWOG A151216: adjuvant lung cancer enrichment marker identification and sequencing trial (ALCHEMIST), Role: PI, Southwest Oncology Group, (10/2024 - 10/2025) Status: Approved
• Apollomics Inc. APL-101-01 (SPARTA): Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors, Role: PI, Apollomics Inc., (09/2024 - 09/2025) Status: Approved
• SWOG S1507: A phase II trial of Trametinib with Docetaxel in patients with KRAS mutation positive non-small cell lung cancer (NSCLC) and progressive disease following one or two prior systematic therapies, Role: PI, Southwest Oncology Group, (05/2023 - 05/2024) Status: Completed
• Caris Life Sciences® and Precision Oncology Alliance™ Retrospective Outcomes-Associated Database, Role: PI, Caris MPI, Inc., (02/2023) Status: Approved
• Novartis CLDK378A2X01B: An open-label, multi-center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored ceritinib (LDK378) study and are judged by the investigator to benefit from continued treatment with ceritinib, Role: PI, Novartis Pharmaceuticals Corporation, (01/2023 - 01/2024) Status: Completed
• Astellas 8951-CL-0301: A phase 3, global, multi-center, double-blind, randomized, efficacy study of Zolbetuximab plus mFOLFOX6 compared with placebo plus mFOLFOX6 as first-line treatment of subjects with Claudin (CLDN) 18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, Role: Investigator, Astellas Pharma US, Inc., (06/2022 - 06/2023) Status: Completed
• C3441021: A Phase 3, Randomized, Double-Blind, Placebo-Controlled study of Talazoparib with Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (TALAPRO-2), Role: Investigator, Pfizer Inc., U.S. Pharmaceuticals Group, (07/2021 - 07/2022) Status: Completed
• Novartis CACZ885V2301: A randomized, double-blind, placebo-controlled, phase III study evaluating the efficacy and safety of canakinumab in combination with docetaxel versus placebo in combination with docetaxel in subjects with non-small cell lung cancer (NSCLC) previously treated with PD(L)1 inhibitors and platinum-based chemotherapy (CANOPY-2), Role: PI, Novartis Pharmaceuticals Corporation, (09/2020 - 09/2021) Status: Completed
• SWOG A031201: Phase III trial of enzalutamide (NSC #766085) versus anzalutamide, abiraterone and prednisone for castration resistant metastatic prostate cancer, Role: Investigator, Southwest Oncology Group, (04/2020 - 04/2021) Status: Completed
• Bio-Cancer Treatment International Ltd.-BCT-100-005: Recombinant human arginase 1 (rhArg1) in patients with advanced, arginine auxotrophic solid tumors: Dose escalation, safety and PK/PD, Role: Investigator, Bio-Cancer Treatment International, Ltd., (04/2020 - 04/2021) Status: Completed
• Novartis - CRAD001Y24135: an open-label, phase II, single-arm study of everolimus in combination with letrozole in the treatment of postmenopausal women with estrogen receptor positive HER2 negative metastatic or locally advanced breast cancer, Role: Investigator, Novartis Pharmaceuticals Corporation, (02/2020 - 02/2021) Status: Completed
• CLDK378A2112: A multi-center, randomized open label study to assess the systemic exposure, efficacy, and safety of 450 mg ceritinib taken with a low-fat meal and 600 mg ceritinib taken with a low-fat meal as compared with that of 750 mg ceritinib taken in the fasted state in adult patients with ALK rearranged (ALK-positive) metastatic non-small cell lung cancer (NSCLC), Role: PI, Novartis Pharmaceuticals Corporation, (01/2020 - 01/2021) Status: Completed
• E5202 Phase III SWOG endorsed CTSU study: a randomized phase III study comparing 5-FU, leucovorin and oxaliplatin versus 5-FU, leucovorin, oxaliptatin and bevacizumab in patients with stage II colon cancer at high risk for recurrence to determine prospectively and prognostic value of molecular markers, Role: Investigator, Southwest Oncology Group, (01/2020 - 01/2021) Status: Completed
• SWOG / NRG-GY009: A Randomized, Phase II/III Study of Pegylated Lipsomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer, Role: Investigator, Southwest Oncology Group, (12/2019) Status: Completed
• SWOG-S1013: A prospective study of epidermal growth receptor (HER-1/EGFR) inhibitor-induced dermatologic toxicity: validation of the functional assessment of cancer therapy-EGFRI 18 (FACT-EGFRI 18) questionnaire for EGFR-induced skin toxicities, Role: PI, Southwest Oncology Group, (09/2019 - 09/2020) Status: Completed
• Southwest Oncology Group (SWOG) protocol #E2805: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma, Role: Investigator, Southwest Oncology Group, (09/2019 - 09/2020) Status: Completed
• SWOG -EAY131: Molecular analysis for therapy choice (MATCH), Role: Investigator, Southwest Oncology Group, (08/2019 - 08/2020) Status: Completed
• Bristol-Myers Squibb - CA204112: A phase 2, single arm study of safety of elotuzumab administered over approximately 60 minutes in combination with lenalidomide and dexamethasone for newly diagnosed or relapsed/refractory multiple myeloma patients, Role: Investigator, Bristol-Myers Squibb Company, (07/2019 - 07/2020) Status: Completed
• SWOG: A221101: A phase III randomized, double-blind placebo controlled study of armodafinil (Nuvigil®) to reduce cancer-related fatigue in patients with high grade glioma, Role: Investigator, Southwest Oncology Group, (05/2019 - 05/2020) Status: Completed
• SWOG S1318: A phase II study of Blinatumomab (NSC-765986) and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for patients >= 65 years of age with newly diagnosed Philadelphia-chromosome negative acute lymphoblastic leukemia (ALL) and of Dasatinib (NSC-732517), Prednisone and Blinatumomab for patients >= 65 years of age with newly diagnosed Philadelphia-chromosome positive (Ph+) ALL, Role: Investigator, Southwest Oncology Group, (08/2018 - 08/2019) Status: Completed
• Southwest Oncology Group (SWOG) - S0800: A randomized phase II trial of weekly nanoparticle albumin bound pacilitaxel (nab-pacilitaxel) (NSC-736631) with or without bevacizumab, either preceded by or followed by Q 2 week doxorubicin (A) and cyclophosphamide (c) plus pegfilgrastim (PEG-G) as neoadjuvant therapy for inflammatory and locally advanced her-2/neu negative breast cancer, Role: Investigator, Southwest Oncology Group, (05/2018 - 05/2019) Status: Completed
• Janssen Research & Development, LLC 54767414LUC2001: A phase 1b/2, open-label, randomized study of daratumumab administered in combination with atezolizumab compared with atezolizumab alone in subjects with previously treated advanced or metastatic non-small cell lung cancer, Role: PI, Janssen Research & Development, LLC, (05/2018 - 05/2019) Status: Completed
• Taiho Oncology Inc. TO-TAS-114-201: A randomized, open-label, multi-center, international phase 2 study of TAS-114 in combination with S-1 in patients with advanced or metastatic non-small cell lung cancer, Role: PI, Taiho Oncology Inc., (10/2017 - 10/2018) Status: Completed
• Mirati Therapeutics,Inc., 265-109: Phase 2, parallel-arm study of MGCD265 in patients with locally advanced or metastatic non-small cell lung cancer with activating genetic alterations in mesenchymal-epithelial transition factor, Role: PI, Mirati Therapeutics, (10/2017 - 10/2018) Status: Completed
• Astellas Pharma Global Development, Inc. 8273-CL-0302: An open-label, randomized phase 3 efficacy study of ASP8273 vs. erlotinib or gefitinib in first-line treatment of patients with stage IIIB/IV non-small cell lung cancer tumors with EGFR activating mutations (SOLAR study), Role: PI, Astellas Pharma US, Inc., (06/2017 - 06/2018) Status: Completed
• Midostaurin (PKC412) Individual Patient Program (IPP) for an individual patient 18 years of age and older with newly-diagnosed FLT3-mutated AML and eligible for standard induction and consolidation chemotherapy, Role: Investigator, Novartis Pharmaceuticals Corporation, (01/2017 - 01/2018) Status: Completed
• Eli Lilly & Co I3Y-MC-JPBK JUNIPER: A randomized phase 3 study of Abemaciclib plus best supportive care versus erlotinib plus best supportive care in patients with stage IV NSCLC with a detectable KRAS mutation who have progressed after platinum-based chemotherapy, Role: PI, Eli Lilly & Co., (11/2016 - 11/2017) Status: Completed
• Pfizer Inc.- A8081014: Phase 3, randomized, open-label study of the efficacy and safety of crizotinib versus pemetrexed/cisplatin or pemetrexed/carboplatin in previously untreated patients with non-squamous carcinoma of the lung harboring a translocation or inversion event involving the anaplastic lymphoma kinase (ALK) gene locus, Role: PI, Pfizer Pharmaceuticals, (07/2016 - 07/2017) Status: Completed
• Millennium Pharmaceuticals, Inc. - C05013: An open-label, randomized, phase 2 study to assess the effectiveness of RCHOP with or without VELCADE® in previously untreated patients with non-germinal center B-Cell-like diffuse large B-cell lymphoma, Role: Investigator, Millennium Pharmaceuticals, Inc., (10/2015 - 10/2016) Status: Completed
• SWOG-9346 Intermittent androgen deprivation in patients with stage D2 Prostate Cancer, Phase III, Role: Investigator, Southwest Oncology Group, (03/2015 - 03/2016) Status: Completed
• SWOG-S0500 - A randomized phase III trial to test the strategy of changing therapy versus maintaining therapy for metastatic breast cancer patients who have elevated circulating tumor cell (CTC) levels at first follow-up assessment, Role: Investigator, Southwest Oncology Group, (09/2014 - 09/2015) Status: Completed
• SWOG N0147. A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab (C225) after Curative Resection for Patients with Stage III Colon Cancer, Role: Investigator, Southwest Oncology Group, (05/2014 - 05/2015) Status: Completed
• Sanofi-aventis - POP6792: Phase I safety and pharmacokinetic study of XRP6258 (cabazitaxel) in advanced solid tumor patients with varying degrees of hepatic impairment, Role: Investigator, Sanofi-Aventis U.S., Inc., (05/2014 - 05/2015) Status: Completed
• Daiichi Sankyo Pharma Development - DS2248-A-U101 - A phase 1, open label, multiple-ascending dose study of DS-2248, an orally biovailable heat shock protein 90 inhibitor in subjects with advance solid tumors, Role: PI, Daiichi Sankyo Pharma Development, (05/2014 - 05/2015) Status: Completed
• SWOG-S0226 - Phase III randomized trial of anastrozole versus anastrozole and fulvestrant as first line therapy for post menopausal women with metastatic breast cancer, Role: Investigator, Southwest Oncology Group, (01/2014 - 01/2015) Status: Completed
• Merrimack Pharmaceuticals - MM-121-01-101: A phase 1-2 trial of MM-121 in combination with erlotinib in three groups of patients with non-small cell lung cancer, Role: PI, Merrimack Pharmaceuticals, (11/2013 - 10/2014) Status: Completed
• Novartis - CSOM230C2303: A multicenter, randomized, blinded efficacy and safety study of pasireotide LAR vs. octreotide LAR in patients with metastatic carcinoid tumors whose disease-related symptoms are inadequately controlled by somatostatin analogues, Role: Investigator, Novartis Pharmaceuticals Corporation, (06/2013 - 06/2014) Status: Completed
• Celgene - protocol CC-5013-MCL-001: A phase II multicenter, single-arm, open-label study to determine the efficacy and safety of single-agent, lenalidomide (Revlimid®) in patients with mantle cell non-Hodgkin's lymphoma who have relapsed or progressed after treatment with bortezomib or are refractory to bortezomib (protocol CC-5013-MCL-001). The "emerge" trial., Role: Investigator, Celgene, Inc., (04/2013 - 04/2014) Status: Completed
• SWOG - S0941: Phase II study of sorafenib (NSC-724772) and erlotinib (NSC-718781) in patients with advanced gallbladder carcinoma or cholangiocarcinoma, Role: Investigator, Southwest Oncology Group, (03/2013 - 03/2014) Status: Completed
• BiPar Sciences Inc. - 20090321: Randomized phase 3 trial of gemcitabine/carboplatin with or without BSI-201 (SAR240550) (a PARP1 inhibitor) in subjects with previously untreated stage IV squamous non-small-cell lung cancer (NSCLC), Role: PI, BiPar Sciences, Inc., (02/2013 - 02/2014) Status: Completed
• Wyeth research division of Wyeth Pharmaceuticals Inc. - 3129K7-2001-WW: A phase II study of inotuzumab ozogamicin (CMC-544) in subjects with indolent non-Hodgkin's lymphoma (NHL) that is refractory to or has relapsed after rituximab and chemotherapy or radioimmunotherapy, Role: Investigator, Wyeth Pharmaceuticals, Inc., (02/2013 - 02/2014) Status: Completed
• Bristol-Myers Squibb - CA 184-043: A randomized, double-blind, phase III trial comparing Ipilimumab vs placebo following radiotherapy in subjects with Castration Resistant Prostate Cancer (CRPC) that have received prior treatment with Docetaxel, Role: Investigator, Bristol-Myers Squibb Company, (12/2012 - 12/2013) Status: Completed
• Novartis - Protocol CRAD001J2101: A phase Ib/II study investigating the combination of RAD001 with trastuzumab and paclitaxel in patients with HER2-overexpressing metastatic breast cancer, Role: PI, Novartis Pharmaceuticals Corporation, (11/2012 - 11/2013) Status: Completed
• Novartis - CZOL446EUS147: A multicenter, open-label, randomized trial to evaluate the anti-cancer effects of zoledronic acid and circulating tumor cell measurements in patients with HER2-negative metastatic breast cancer without bone metastasis, Role: Investigator, Novartis Pharmaceuticals Corporation, (08/2012 - 08/2013) Status: Completed
• BMS - CA182-034: A randomized, double-blind, multi-center phase III study of brivanib plus best supportive care (BSC) versus placebo plus BSC in subjects with advanced hepatocellular carcinoma (HCC) who have failed or are intolerant to sorafenib: the BRISK PS study, Role: Investigator, Bristol-Myers Squibb Company, (10/2011 - 10/2012) Status: Completed
• Oncotherapeutics - C10953/6270: A phase III study of armodafinil for the treatment of cancer-related fatigue for patients with multiple myeloma, Role: Investigator, Oncotherapeutics, (08/2011 - 08/2012) Status: Completed
• AMGEN-20060464: A phase 1b/2 study of AMG 655 in combination with modified FOLFOX6 and bevacozimab for the first line treatment of subjects with metastatic colorectal cancer, Role: Investigator, Amgen, Inc., (07/2011 - 07/2012) Status: Completed
• NewLink Genetics Corporation - NLG-0405: A phase III study of chemotherapy and chemoradiotherapy with or without HyperAcute - pancreatic (Algenpantucel-L) immunotherapy in subjects with surgically resected pancreatic cancer, Role: Investigator, NewLink Genetics Corporation, (07/2011 - 07/2012) Status: Completed
• GlaxoSmithKline (GSK)-LPT109747 - An exploratory, phase II trial to determine the association of lapatinib induced fluoropyrimidine gene changes with efficacy parameters of lapatinib and capecitabine in first line gastric cancer, Role: Investigator, GlaxoSmithKline, (05/2011 - 05/2012) Status: Completed
• Genmab-GEN205 - An open label single arm trial investigating zalutumumab, a human monoclonal anti-EGF receptor antibody, in combination with palliative care in patients with non-curable squamous cell carcinoma of the head and neck who have failed standard platinum-based chemotherapy, Role: Investigator, GENMAB, (05/2011 - 05/2012) Status: Completed
• CTI-PIX203 Cyclophosphamide, doxorubicin, vincristine, prednisone plus rituximab (CHOP-R) and cyclophosphamide, pixantrone, vincristine, prednisone plus rituximab (CPOP-R) in elderly patients with diffuse large-B-cell lymphoma a phase II randomized, multicenter, comparative trial., Role: Investigator, Cell Therapeutics, Inc., (04/2011 - 04/2012) Status: Completed
• Oncotherapeutics - DVD-R-2009: A phase II study of pegylated liposomal doxorubicin, bortezomib, dexamethasone and lenalidomide (DVD-R) for patients with relapsed/refractory multiple myeloma, Role: Investigator, Oncotherapeutics, (04/2011 - 04/2012) Status: Completed
• OSI-774-302: A multi-center, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors (RADIANT), Role: PI, OSI Pharmaceuticals, Inc., (02/2011 - 02/2012) Status: Completed
• Abraxis Bioscience, LLC - CA033: An open label, multicenter, phase III trial of ABI-007 vs dacarbazine in previously untreated patients with metastatic malignant melanoma, Role: Investigator, Abraxis BioScience, (02/2011 - 02/2012) Status: Completed
• Sanofi-Aventis-EFC 10261: A multi-center, randomized, double-blind study comparing aflibercept versus placebo in patients treated with second-line docetaxel after failure of one platinum based therapy for locally advanced or metastatic non-small cell lung cancer (NSCLC), Role: PI, Sanofi-Aventis U.S., Inc., (01/2011 - 01/2012) Status: Completed
• Oncotherapeutics - X05272/DOXILMMY2010: A phase II study of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) for patients with newly diagnosed Multiple Myeloma (MM), Role: Investigator, Oncotherapeutics, (10/2010 - 10/2011) Status: Completed
• Millennium Pharmaceuticals, Inc. protocol C05012 - A two-arm, non-randomized, multicenter, phase 2 study of Velcade® (bortezomib) in combination with rituximab, cyclophosphamide, and prednisone with or without doxorubicin followed by rituximab maintenance in subjects with relapsed follicular lymphoma, Role: Investigator, Millennium Pharmaceuticals, Inc., (08/2010 - 08/2011) Status: Completed
• Aptium 05LUN01 - A phase I/II clinical trial of bortezomib (velcade) + pemetrexed (alimta) in previously treated patients with advanced non-small cell lung cancer, Role: PI, Aptium Oncology Research Network, (06/2010 - 06/2011) Status: Completed
• Genentech - protocol AVF3671g: a randomized, double blind, placebo controlled, phase IIIb trial comparing bevacizumab therapy with or without erlotinib after completion of chemotherapy with bevacizumab for first line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer, Role: PI, Genentech, Inc., (04/2010 - 03/2011) Status: Completed
• Gloucester Pharmaceuticals, Inc. - GPI-08-0006: A phase II trial of romidepsin and bortezomib for multiple myeloma patients with relapsed or refractory disease, Role: Investigator, Gloucester Pharmaceuticals, Inc., (02/2010 - 02/2011) Status: Completed
• Novartis - CASA404A2301: A phase III, randomized, double-blind, placebo-controlled multi-center study of ASA404 in combination with paclitaxel and carboplatin as first-line treatment for locally advanced or metastatic (stage IIIb/IV) non small-cell lung cancer (NSCLC), Role: PI, Novartis Pharmaceuticals Corporation, (01/2010 - 01/2011) Status: Completed
• Dendreon Corporation, Protocol D9902B: A randomized, double blind, placebo controlled trial of immunotherapy with autologous antigen presenting cells loaded with PA2024 (Provenge®, APC8015) in men with metastatic androgen independent prostatic adenocarcenoma, Role: Investigator, Dendreon Corporation, (09/2009 - 09/2010) Status: Completed
• Wyeth - 3129K4-3301-WW - An open-label, randomized, phase 3 study of inotuzumab ozogamicin (CMC- 544) administered in combination with rituximab compared to a defined investigator's choice therapy in subjects with relapsed or refractory, CD22-positive, follicular b-cell Non-Hodgkin's lymphoma, Role: Investigator, Wyeth Pharmaceuticals, Inc., (10/2008 - 10/2009) Status: Completed
• SWOG-S0622 - Phase II studies of two different schedules of dasatinib (NSC-732517) in bone-metastasis predominant metastatic breast cancer, Role: Investigator, Southwest Oncology Group, (06/2008 - 06/2009) Status: Completed
• AT-101-CS-101 An open-label, multicenter, phase I/II study of AT-101 in combination with topotecan in patients with relapsed or refractory small cell lung cancer after prior platinum containing first line chemotherapy, Role: PI, Ascenta Therapeutics Inc., (01/2008 - 01/2009) Status: Completed
• SWOG/NRG LU003: A Biomarker-Driven protocol for previously treated ALK-Positive Non-Squamous NSCLC patients: The NCI-NRG ALK protocol, Role: PI, Southwest Oncology Group, Status: Completed
• SWOG A041701: A randomized phase II/III study of conventional chemotherapy +/- uproleselan (GMI-1271) in older adults with acute Myeloid Leukemia receiving intensive induction chemotherapy, Role: Investigator, Southwest Oncology Group, Status: Completed
• LUNGMAP, “A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Preciously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)” S1900F, “A Randomized Phase II Study of Carboplatin and Pemetrexed with or Without Selpercatinib (LY3527723) in Participants with Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy (Lung-MAP Sub-Study)”, Role: PI, Southwest Oncology Group, Status: Completed
• A Phase 1b/2 Study Assessing the Safety and Efficacy of Evexomostat (SDX-7320) in Combination with a PI3K Pathway Inhibitor plus Fulvestrant in Postmenopausal Women with Advanced Breast Cancer and PII3K Pathway Alterations Who Have Progressed on or Following Endocrine Therapy plus a CDK4/6 Inhibitor, Role: Investigator, SynDevRx, Inc., (02/2025 - 02/2026) Status: Approved

Internal

• A phase II trial of proton chemotherapy (PCT) for resectable esophageal or esophagogastric junction cancer, Role: Investigator, LLU Dept. of Radiation Medicine, (08/2024 - 08/2025) Status: Approved
• Phase II trial of partial breast proton therapy for early stage breast cancer with low and intermediate risk factors, Role: Investigator, LLU Dept. of Radiation Medicine, (08/2024 - 07/2025) Status: Approved
• Phase II trial of lumpectomy and partial breast proton therapy for early stage breast cancer, Role: Investigator, LLU Dept. of Radiation Medicine, (06/2024 - 06/2025) Status: Approved
• Investigator initiated CIPNGRASP: A pilot study of intraneural facilitation for managing chemotherapy-induced peripheral neuropathy, Role: Investigator, LLU Dept. of Medicine, (04/2025 - 04/2026) Status: Approved
• Investigator Initiated: A phase II trial of preoperative chemotherapy (with gemcitabine and nab-paclitaxel) and stereotactic body radiotherapy followed by surgery and chemotherapy in patients with resectable pancreatic adenocarcinoma, Role: Investigator, LLU Dept. of Surgery, (09/2024 - 09/2025) Status: Approved
• Investigator Initiated: Association Between County Level Social Vulnerability Index (SVI) and Receipt of lmmunotherapy for Unresectable Stage Ill and Stage IV Metastatic Non-Small Cell Lung Cancer (NSCLC), Role: PI, LLU Dept. of Medicine, (06/2021) Status: Approved
• A retrospective study of clinico- pathologic disparities in breast cancer in Hispanic versus non-Hispanic patients population, Role: PI, LLU Dept. of Medicine, (03/2017 - 02/2018) Status: Completed
• Retrospective study of difference in rates of recurrence in early stage lung cancer in patients treated with VATS vs open thoracotomy, Role: PI, LLU Dept. of Medicine, (11/2016 - 10/2017) Status: Completed
• Phase I/II study of combined chemotherapy and high dose, accelerated proton radiation for the treatment of locally advanced non-small cell lung carcinoma, Role: Investigator, LLU Dept. of Radiation Medicine, (03/2013 - 03/2014) Status: Completed
• Retrospective comparative evaluation of epidermal growth factor receptive inhibitors-induced dermatologic toxicities between Japan and United States: Is there a difference?, Role: Investigator, LLU School of Pharmacy, (09/2012 - 09/2013) Status: Completed
• Phase II trial of outpatient intravenous interleukin-2 in malignant melanoma and metastatic kidney cancer, Role: Investigator, LLU Dept. of Medicine, (02/2012 - 02/2013) Status: Completed
• Emergency use of brigatinib, Role: PI, LLU Dept. of Medicine, Status: Completed
• LLU Cancer Center biospecimen laboratory - specimens collection protocol, Role: Investigator, LLU Cancer Institute, (09/2024 - 09/2025) Status: Approved
• Uncommon EGFR mutations and compound EGFR mutations in NSCLC and their response to EGFR inhibitors, Role: PI, LLU Cancer Institute, (04/2025) Status: Approved
• Quality of Life in Sickle Cell Disease Patients Treated with Red Blood Cell Apheresis, Role: Investigator, LLU Dept. of Medicine, (03/2025) Status: Approved

Non-Profit Organization

• NSABP Protocol B-42: a clinical trial to determine the efficacy of five years of letrozole compared to placebo in patients competing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor positive breast cancer, Role: PI, National Surgical Adjuvant Breast & Bowel Project, (06/2024 - 06/2025) Status: Approved
• NSABP B52: A randomized phase III trial evaluating pathologic complete response rates in patients with hormone receptor-positive, HER2-positive, large operable and locally advanced breast cancer treated with neoadjuvant therapy of docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) with or without estrogen deprivation, Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (06/2024 - 06/2025) Status: Approved
• NSABP-B31 - A randomized trial comparing the safety and efficacy of adriamycin and cyclophosphamide followed by taxol (AC-T) to that of adriamycin and cyclophosphmide followed by taxol plus herceptin (AC-T+HC) in node-positive breast cancer patients who have tumors that overexpress HER2., Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (12/2019 - 12/2020) Status: Completed
• NSABP B-58: A randomized open-label, phase 3 study of abemaciclib combined with standard adjuvant endocrine therapy alone in patients with high risk, node positive, early stage, hormone receptor positive, human epidermal receptor 2 negative breast cancer, Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (10/2019 - 10/2020) Status: Completed
• National surgical adjuvant breast and bowel project (NSABP) protocol #B-40: A randomized phase III trial of neoadjuvant therapy in patients with palpable and operable breast cancer evaluating the effect on pathologic complete response (pCR) of adding capecitabine or gemcitabine to docetaxel when administered before, Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (05/2018 - 05/2019) Status: Completed
• NSABP-B-38 - A Phase III, adjuvant trial comparing three chemotherapy regiments in women with node-positive breast cancer: docetaxel/doxorubicin/cyclophosphamide (TAC); dose-dense (DD) doxorubicin/cyclophosphamide followed by DD paclitaxel (DD AC P); DD AC followed by DD paclitaxel plus gemcitabine (DD AC PG), Role: PI, National Surgical Adjuvant Breast & Bowel Project, (11/2015 - 11/2016) Status: Completed
• NSABP-B-36 - A clinical trial of adjuvant therapy comparing six cycles of 5-fluorouracil, epirubicin and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients with node-negative breast cancer, Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (08/2015 - 08/2016) Status: Completed
• National Surgical adjuvant breast and bowel project (NSABP) R-04 a clinical trial comparing preoperative radiation therapy and capecitabine with or with out oxaliplatin with preoperative radiation therapy and continuous intravenous infusion of 5-fluorouracil with or without oxaliplatin in the treatment of patients with operable carcinoma of the rectum, Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (05/2014 - 05/2015) Status: Completed
• NSABP - B32 - A randomized, phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node-negative breast cancer patients, Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (09/2013 - 09/2014) Status: Completed
• NSABP P-2 - Study of tamoxifen and raloxifene (STAR) for the prevention of breast cancer, Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (06/2012 - 06/2013) Status: Completed
• NSABP-B30. A three-armed randomized trial to compare adjuvant adriamycin and cyclophosphamide followed by toxotere (AC-T); adriamycin and toxotere (AT); and adriamycin, taxotere, and cyclophosphamide (ATC) in breast cancer patients with positive axillary lymph nodes, Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (03/2012 - 03/2013) Status: Completed
• NSABP-B34 - A clinical trial comparing adjuvant clondronate therapy vs placebo in early-stage breast cancer patients receiving systemic chemotherapy and/or hormonal or no therapy, Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (02/2012 - 02/2013) Status: Completed
• Protocol BMS-CA 180-188 - Dasatinib in chronic myelogenous leukemia or Philadelphia chromosome positive acute lymphoblastic subjects who are experiencing clinical benefit on current START protocols: Long term safety and efficacy, Role: Investigator, Bristol-Myers Squibb Foundation, Inc., (11/2010 - 11/2011) Status: Completed
• NSABP B-27: A randomized trial comparing preoperative doxorubicin cyclophosphamide to preoperative AC followed by preoperative docetaxel and to preoperative AC followed by postoperative docetaxel in patients with operable carcinoma of the breast, Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (03/2010 - 03/2011) Status: Completed
• NSABP B-28. A Randomized Trial Evaluating the Worth of Paclitaxol (Taxol) Following Doxorubicin (Adriamycin)/Cyclophosphamide in Breast Cancer Patients with Positive Axillary Nodes, Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (11/2008 - 11/2009) Status: Completed
• NSABP PROTOCOL C-09: A phase II clinical trial comparing oxaliplatin, capecitabine and hepatic arterial infusion of floxuridine to oxaliplatin and capecitabine in patients with resected or ablated liver metastases from colorectal cancer, Role: Investigator, National Surgical Adjuvant Breast & Bowel Project, (11/2008 - 11/2009) Status: Completed